Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (1622)	6/6/2003 9:49:23 AM
From: Biomaven	Respond to of 3044

Because of the MLNM own infrastructure they can explore Velcade (from genomic-pharmacogenomic to predictive and personalized medicine) in a way that no pharma or bios can do it today. This is advantage. I hope that they will apply some methodology on all candidates. I think Miljenko (as always) put his finger on a key issue here. MLNM's "advantage" may not be in drug discovery after all, but in clinical development. If they can bring to other oncology drugs what they brought to Velcade's development, they will surely do well. The days of traditional oncology drug development - pick a bunch of cancers and try your drug in them, and then take the most promising cancer and run some big trials to see how it turns out - are surely numbered. As we get a better idea of how cancers work, the clinical development programs have to be upgraded to take advantage of this knowledge. Thus their change in emphasis makes a lot of sense to me. Perhaps we will see them partner or in-license some new drug candidates - KOSN's 17-AAG seems like a logical choice to me given its possible synergy with Velcade. Peter